AbbVie’s hepatitis C virus (HCV) regimen Mavyret (glecaprevir/pibrentasvir) is highly effective among those with genotype 3 of the virus, considered the most difficult genotype to treat.

Presenting their findings at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, DC, researchers conducted an analysis of safety and efficacy data from five Phase II and III studies of Mavyret among 571 individuals with genotype 3 of hep C who were first-timers to treatment.

The 69 individuals with cirrhosis were all treated for 12 weeks, while a respective 208 and 294 people without cirrhosis were treated for 8 and 12 weeks. Among those without cirrhosis, the proportion who had advanced fibrosis (F3 on the Metavir scoring system) was 18 percent (38 of 208) among those treated for eight weeks and 11 percent (31 of 294) among those treated for 12 weeks.

Among those without cirrhosis, the proportion that achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure) was a respective 95 percent (198 of 208) and 95 percent (280 of 294) among those treated for eight and 12 weeks. The cure rate among those with cirrhosis was 97 percent (67 of 69).

The most common adverse health events, occurring in at least 10 percent of participants, were headache, fatigue and nausea. No participant experienced a serious adverse health event considered related to Mavyret. Serious adverse health events leading individuals to stop treatment were rare.

To read the conference abstract, click here.